Table 1.

List of autoinjector devices for the administration of some drugs in use and under clinical trials (Vijayaraghavan, 2020).

Clinical condition	Autoinjector device	Route of administration	Dosage forms Strength	Dose
Anaphylaxis	Epinephrine (EpiPen) Omalizumab (Xolair**)	i.m. s.c.	0.3 mg & 0.15 mg 75 mg/0.5 mL	0.3 mg 150 mg/mL
Seizures	Diazepam Midazolam	i.m. i.m.	10 mg 10 mg/2 mL or 5 mg/mL	10 mg-20 mg 5 mg-10 mg
Organophosphorus poisoning	Atropine (AtroPen®) Pralidoxime Pralidoxime + Atropine (DuoDote® autoinjector)	i.m. i.m. i.m	0.5 mg/1 mg/2 mg 600 mg/2 mL (Pralidoxime 600 mg/2 mL + Atropine 2.1 mg/0.7 mL)	1–2 g
Migraine	Sumatriptan (ZEMBRACE® SymTouch®)	s.c.	3 mg	3–12 mg/day
Opioid overdose	Naloxone (Evzio)	i.m./s.c.	0.4 mg & 2 mg/0.4 mL	0.4 mg-2 mg
Psoriasis	Ixekizumab (TALTZ) Secukinumab (Cosentyx) Certolizumab pegol (cimzia)	s.c. s.c. s.c.	80 mg/mL 150 mg or 300 mg 200 mg/mL
Rheumatoid arthritis	Sirukumab (PLIVENSIA™) Sarilumab (KEVZARA) Tocilizumab (ACTpen) Certolizumab pegol Golimumab (SIMPONI) Adalimumab (Humira pen) Methotrexate (Otrexup) Etanercept (Enbrel®)	s.c. s.c. s.c. s.c. s.c. s.c. s.c. s.c	50 mg, 100 mg 200 mg 62 mg/0.9 mL 200 mg/mL 40 mg/0.8 mL 10, 15, 20, and 25 mg 50 mg/mL	Q4W Q2W Q2W 50 mg once a month (7.5–25 mg/week) 50 mg/week
Multiple sclerosis	Interferon β-1a (Avonex) Interferon β-1b (ExtaviPro™)	i.m s.c	30 μg 0.3 mg.	30 μg/week 0.0625 mg alternate day
Systemic lupus erythematosus	Belimumab (Benlysta)	s.c.	200 mg/mL	200 mg/week
Erectile dysfunction	Aviptadil/phentolamine	i. c.	2 μg/2 mg
Analgesic	Buprenorphine*	i.m.
Diabetes	Insulin (KwikPen) Exenatide (Exenatide QWS AI)	s.c. s.c.	100 unit/200 units/3 mL pen 2 mg	10 units/day 2 mg/week
Antibacterial	Amikacin* Amikacin + Cefazolin*	i.m. i.m.	500 mg 250 mg + 250 mg 250 mg +	500 mg/day 250 mg/day
Hypercholesterolaemia	Evolocumab (SureClick) Alirocumab	s.c. s.c.	140 mg/mL 75	Q2W mg/mL single-dose pre-filled pen

i.m. - intramuscular, s.c. - subcutaneous, i.c. – intracorporeal, * only in animal model.

** Pre-filled syringe-s.